dimemorfan: RN given refers to parent cpd without isomeric designation; synonym At 17 refers to phosphate[1:1] salt; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3037918 |
| CHEMBL ID | 2106325 |
| CHEBI ID | 135048 |
| SCHEMBL ID | 499349 |
| MeSH ID | M0059769 |
| Synonym |
|---|
| dimemorfan |
| CHEBI:135048 |
| dimemorfan [inn] |
| 36309-01-0 |
| 36304-82-2 |
| at 17 |
| 3,17-dimethylmorphinan |
| d-3-methyl-n-methylmorphinan |
| 623oac38yu , |
| dimemorfano [inn-spanish] |
| dimemorfanum [inn-latin] |
| einecs 252-963-3 |
| dimemorfanum |
| dimemorfano |
| 3,n-dimethylmorphinan [iupac] |
| (+)-3,17-dimethylmorphinan |
| dimemorfane [inn-french] |
| unii-623oac38yu |
| dimemorfane |
| dimemorphan |
| morphinan, 3,17-dimethyl-, (9alpha,13alpha,14alpha)- |
| 3,n-dimethylmorphinan |
| n,3-dimethylmorphinan |
| CHEMBL2106325 |
| dimemorfan [who-dd] |
| dimemorfan [mi] |
| SCHEMBL499349 |
| Q5277240 |
| DB13810 |
| (1s,9s,10s)-4,17-dimethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene |
| us11535596, compound dimemorfan (dim) |
| bdbm587503 |
| DTXSID301043335 |
Dimemorfan phosphate has been widely used for 40 years throughout the world for the treatment of coughs. It has been known to possess neuroprotective properties.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dimemorfan phosphate has been widely used for 40 years throughout the world for the treatment of coughs. " | ( Simple and sensitive LC-MS/MS-based assay for the quantification of dimemorfan in human plasma for use in a pharmacokinetic study. Chen, J; Guo, C; Hua, Y; Pei, Q; Peng, J; Tan, H; Yang, G; Yang, L; Yuan, H, 2015) | 2.1 |
| "Dimemorfan (DF) has been known to possess neuroprotective properties. " | ( Concise synthesis of dimemorfan (DF) starting from 3-hydroxymorphinan (3-HM). Kim, HC; Kim, J; Kim, JY; Lee, J, 2008) | 2.11 |
Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. Pre-treatment with dimmorfan (12 or 24 mg kg(-1) reduced seizures in a dose-dependent manner.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus." | ( The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Cha, JY; Chen, CF; Jhoo, WK; Kim, HC; Kim, WK; Ko, KH; Lim, YK; Nah, SY; Shin, EJ, 2005) | 1.34 |
| "Dimemorfan treatment (10 microg/kg, i.v., at the time of reperfusion) inhibited the expressions of monocyte chemoattractant protein-1 and interleukin-1beta, which occurred in parallel with decreases in neutrophil infiltration, activation of inflammation-related signals (p38 mitogen-activated protein kinase, nuclear factor-kappaB, and signal transducer and activator of transcription-1), expression of neuronal and inducible nitric oxide synthase, oxidative/nitrosative tissue damage (lipid peroxidation, protein nitrosylation, and 8-hydroxy-guanine formation), and apoptosis in the ipsilateral cortex after CI/R injury." | ( Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. Chou, YC; Liao, JF; Liou, KT; Shen, YC; Wang, WY; Wang, YH; Yen, JC, 2008) | 2.51 |
| "Pre-treatment with dimemorfan (12 or 24 mg kg(-1)) reduced seizures in a dose-dependent manner." | ( The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Cha, JY; Chen, CF; Jhoo, WK; Kim, HC; Kim, WK; Ko, KH; Lim, YK; Nah, SY; Shin, EJ, 2005) | 0.94 |
| "Treatment with dimemorfan (1.0 microg/kg and 10 microg/kg, i.v.) either 15 min before ischemia or at the time of reperfusion, like the putative sigma(1) receptor agonist, PRE084 (10 microg/kg, i.v.), ameliorated the size of the infarct zone by 67-72% or 51-52%, respectively, which was reversed by pre-treatment with the selective sigma(1) receptor antagonist, BD1047 (20 microg/kg, i.v.)." | ( Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. Chou, YC; Liao, JF; Liou, KT; Shen, YC; Wang, WY; Wang, YH; Yen, JC, 2008) | 2.13 |
The developed method was successfully applied for the determination of dimemorfan in a pharmacokinetic study using healthy Chinese subjects. Data were evaluated from 24 subjects who received an oral dose of 40 mg of dimmorfan syrup (n = 12) or dimemfran tablet (n =12)
| Excerpt | Reference | Relevance |
|---|---|---|
| " Data were evaluated from 24 subjects in two pharmacokinetic studies who received an oral dose of 40 mg of dimemorfan syrup (n = 12) or dimemorfan tablet (n = 12) after providing written informed consent and being divided into three groups: subjects with CYP2D6*10 CC (n = 5), CYP2D6*10 CT (n = 11) and CYP2D6*10 TT (n = 8)." | ( Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects. Liu, L; Liu, S; Pei, Q; Peng, J; Tan, H; Yang, G; Yang, L; Yang, X; Yuan, H, 2015) | 0.87 |
| " Finally, the developed method was successfully applied for the determination of dimemorfan in a pharmacokinetic study using healthy Chinese subjects." | ( Simple and sensitive LC-MS/MS-based assay for the quantification of dimemorfan in human plasma for use in a pharmacokinetic study. Chen, J; Guo, C; Hua, Y; Pei, Q; Peng, J; Tan, H; Yang, G; Yang, L; Yuan, H, 2015) | 0.88 |
| "Investigate the pharmacokinetic properties of the antitussive dimemorfan phosphate tablets in healthy male and female Chinese volunteers after single and multiple-dose administration; and to evaluate the food-effect on pharmacokinetics of dimemorfan." | ( Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers. Luo, Z; Miao, J; Shen, Y; Wang, Y; Xiang, J; Yu, Q, 2017) | 1.02 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " We demonstrated that cytochrome P450 2D6*10 (100C > T, rs1065852) polymorphism can affect the pharmacokinetics of dimemorfan in humans, not dosage forms." | ( Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects. Liu, L; Liu, S; Pei, Q; Peng, J; Tan, H; Yang, G; Yang, L; Yang, X; Yuan, H, 2015) | 0.87 |
| Class | Description |
|---|---|
| morphinane alkaloid | An isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (23.81) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (9.09%) | 5.53% |
| Reviews | 1 (4.55%) | 6.00% |
| Case Studies | 1 (4.55%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (81.82%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||